KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Asset Writedowns and Impairment (2022 - 2025)

Charles River Laboratories International has reported Asset Writedowns and Impairment over the past 4 years, most recently at $7.9 million for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at $7.9 million for Q4 2025, down 70.8% from a year ago — trailing twelve months through Dec 2025 was $12.4 million (down 64.67% YoY), and the annual figure for FY2025 was $12.4 million, down 15.77%.
  • Asset Writedowns and Impairment for Q4 2025 was $7.9 million at Charles River Laboratories International, up from -$26.6 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for CRL hit a ceiling of $29.2 million in Q2 2025 and a floor of -$26.6 million in Q3 2025.
  • Median Asset Writedowns and Impairment over the past 4 years was $6.7 million (2022), compared with a mean of $5.6 million.
  • Biggest five-year swings in Asset Writedowns and Impairment: soared 1543.21% in 2024 and later plummeted 342.08% in 2025.
  • Charles River Laboratories International's Asset Writedowns and Impairment stood at $6.7 million in 2022, then plummeted by 218.95% to -$8.0 million in 2023, then surged by 438.47% to $27.0 million in 2024, then tumbled by 70.8% to $7.9 million in 2025.
  • The last three reported values for Asset Writedowns and Impairment were $7.9 million (Q4 2025), -$26.6 million (Q3 2025), and $29.2 million (Q2 2025) per Business Quant data.